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A B S T R A C T
CCT241736 is a dual fms-like tyrosine kinase 3 (FLT3)/Aurora kinase inhibitor in development for the treatment
of acute myeloid leukaemia. The successful development of any new drug relies on adequate safety testing
including preclinical toxicology studies. Selection of an appropriate preclinical species requires a thorough
understanding of the compound's metabolic clearance and pathways, as well as other pharmacokinetic and
pharmacodynamic considerations. In addition, elucidation of the metabolising enzymes in human facilitates
improved clinical prediction based on population pharmacokinetics and can inform drug-drug interaction stu-
dies. Intrinsic clearance (CLint) determination and metabolite profiling of CCT241736 in human and four pre-
clinical species (dog, minipig, rat and mouse) was undertaken in cryopreserved hepatocytes and liver micro-
somes. Recombinant human cytochrome P450 bactosomes (rCYP) were utilised to provide reaction phenotyping
data and support prediction of metabolic pathways. CCT241736 exhibited low CLint in both hepatocytes and
liver microsomes of human, dog, minipig and rat, but considerably higher CLint in mouse. CYP3A4 and CYP3A5
were identified as the major enzymes responsible for biotransformation of CCT241736 in human, exclusively
forming five out of seven metabolites. Minipig showed greatest similarity to human with regard to both overall
metabolic profile and abundance of specific metabolites relative to parent compound, and is therefore proposed
as the most appropriate toxicological species. The greatest disparity was observed between human and dog.
Based on metabolic profile, either mouse or rat is a suitable rodent species for toxicology studies.
1. Introduction
The family of highly homologous serine/threonine kinases known as
Aurora (A, B and C) is fundamental in cell mitosis, each isoform reg-
ulating discrete yet pivotal processes necessary for successful cell di-
vision. Aurora-A, predominantly localised to centrosomes and attached
microtubules, has important functions in centrosome maturation as
well as spindle assembly and orientation during metaphase I (Carmena
and Earnshaw, 2003). Aurora-B forms a complex with two additional
proteins at the centromere and is involved in governing chromosome
condensation and orientation, interactions between the kinetochore
and cytoskeleton, and cytokinesis (Carmena and Earnshaw, 2003). Less
is known about the role of Aurora-C, which is thought only to be ex-
pressed the testis, thyroid, placenta and gametes undergoing meiotic
division (Bernard et al., 1998; Carmena and Earnshaw, 2003; Kimura
et al., 1999; Ulisse et al., 2006; Yang et al., 2010). Overexpression of
Aurora-A (Bischoff et al., 1998; Gritsko et al., 2003; Reichardt et al.,
2003; Tanaka et al., 1999; Zhou et al., 1998)) and Aurora-B (Araki
et al., 2004; Chieffi et al., 2004; Sorrentino et al., 2005) has been re-
ported across a number of human malignancies including glioma,
breast, ovarian, pancreatic and colon cancer. Inhibition of either
Aurora-A or Aurora-B results in cell death, mediated via different me-
chanisms related to the isoforms' distinct functions (Kaestner et al.,
2009). Development of Aurora kinase inhibitors therefore became an
attractive pharmaceutical strategy with the goal to treat both solid tu-
mours and hematologic cancers, the latter of which was successful,
particularly in acute myeloid leukaemia (AML) (Bavetsias and
Linardopoulos, 2015). Although single isoform specific Aurora
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inhibitors were developed, pan-Aurora inhibitors and even those with
an additional anti-cancer pharmacology, such as fms-like tyrosine ki-
nase 3 (FLT3) inhibition were also pursued (Bavetsias and
Linardopoulos, 2015; Pollard and Mortimore, 2009).
FLT3 is a tyrosine kinase receptor of the platelet-derived growth
factor receptor (PDGF-R) sub-family. Both overexpression and acti-
vating mutations, including internal tandem duplication (FLT3-ITD), of
this receptor have been identified in human leukaemic cell lines (Levis
and Small, 2003) and are associated with a poor prognosis in AML
(Moore et al., 2010), highlighting it as a potential pharmacological
target. However, single agent FLT3 inhibitors developed for the treat-
ment of AML, such as sorafenib and AC220, rapidly elicited acquired
resistance (Knapper, 2011). Simultaneous targeting of the Aurora ki-
nases and FLT3 was therefore hypothesised, and subsequently demon-
strated to be a promising approach to AML therapy (Bavetsias et al.,
2012).
6-Chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-
1Hpyrazol-4-yl)-3H-imidazo[4,5-b] pyridine (CCT241736, also referred
to as Compound 27e in Bavetsias et al. (2012)), is a dual FLT3 and
Aurora kinase inhibitor in pre-clinical development for the treatment of
AML. CCT241736 exhibits potent inhibition of FLT3 (Kd=6.2 nM),
FLT3-ITD (Kd=38 nM) and Aurora-A and Aurora-B kinases
(Kd= 7.5 nM and 48 nM, respectively) (Bavetsias et al., 2012).
CCT241736 exhibited anti-proliferative activity against HCT116
(human colon carcinoma), MOLM-13 and MV4-11 (human FLT3-ITD
positive AML) cell lines, as well as strong inhibition of tumour growth
in an MV4-11 xenograft mouse model (Bavetsias et al., 2012). In a 4-
day mouse PK/PD study, administration of CCT241736 p.o. at 50 and
100mg/kg b.i.d. resulted in biomarker modulation (histone H-3 and
STAT5 phosphorylation) consistent with target inhibition (Bavetsias
et al., 2012). Relative to its predecessor (Compound 6, (Bavetsias et al.,
2012)), CCT241736 was specifically optimised to reduce hERG
blockade (IC50> 25 μM) and in vitro microsomal metabolism. Phar-
macokinetic studies of CCT241736 in mouse and rat revealed moderate
(48ml/min/kg) and low (4.57ml/min/kg) clearance, respectively, and
high oral bioavailability (79–100%) consistent with reported Caco-2
permeability of 18.6×10−6 cm/s, with no evidence of efflux
(Bavetsias et al., 2012). Additionally, a cytochrome P450 (CYP) in-
hibition screen showed no significant inhibition of CYP1A2, CYP2A6,
CYP2C9, CYP2C19, CYP2D6 or CYP3A4; all IC50 values were >10 μM
(Bavetsias et al., 2012). Thus, CCT241736 was considered to possess
properties suitable for further development.
Prior to administration to humans, a drug candidate must undergo
nonclinical safety evaluation, typically animal toxicology studies,
which assess drug exposure and associated adverse events. Such studies
should, where possible, be undertaken in a species which reflects
human risk, preferably with a similar pharmacology, pharmacokinetic
and metabolic profile (U.S. Department of Health and Human Services
Food and Drug Administration Center for Drug Evaluation and Research
(CDER), 2016). As it is not uncommon for the metabolism of a com-
pound to differ across species, both quantitatively and qualitatively,
selection should be guided by prior in vitro and/or in vivo metabolic
characterisation. The U.S. Department of Health and Human Services
Food and Drug Administration Center for Drug Evaluation and Research
(CDER) (2016) guidance suggests that any metabolite which is dis-
proportionately higher in human than the studied animal species
should undergo separate safety evaluation, and additionally, that any
human metabolite predicted to have >10% of total drug exposure
should be characterised and monitored in clinical trials. In vitro meta-
bolic profiling can therefore prove to be useful in both appropriate
selection of toxicological species and clinical trial design. Furthermore,
elucidation of the human enzymes responsible for metabolism of a
compound can guide both in vitro and clinical drug-drug interaction
studies and facilitate improved human prediction based on population
pharmacokinetics.
Early in drug discovery, large scale screening of metabolic clearance
in liver microsomes is an efficient and cost-effective method by which
to support structural drug design through the identification of labile
groups and to highlight significant species differences. However, due to
their subcellular nature, microsomes provide only a limited perspective
of metabolism in vivo; xenobiotic biotransformation is dependent on the
experimental conditions and exogenously supplied cofactors (typically
reduced nicotinamide adenine dinucleotide phosphate (NADPH) and
increasingly uridine 5′-diphospho-glucuronic acid (UDPGA)), and is
unrestricted by plasma membrane permeability. As prediction to pre-
clinical species and to human becomes more relevant, use of in vitro
systems of increasing complexity (subcellular fractions to whole cells
and even organ- or multiple organ-microfluidic systems) which greater
mimic the in vivo situation, may be advantageous (Bhatia and Ingber,
2014; De Bartolo et al., 2006). Cryopreserved hepatocytes are often
utilised to provide a more comprehensive assessment of metabolism
due to their ‘off-the-shelf’ availability across multiple species and re-
ference as the ‘gold standard’ for hepatic metabolic clearance de-
terminations (Hewitt et al., 2007). Their full complement of metabolic
enzymes and transporters allow assessment of metabolism, uptake and
even biliary clearance when used in the appropriate format, including
monolayer- and sandwich-culture, but their cost often precludes use in
high-throughput settings. Lastly, fundamental systems may still serve to
provide specific information, for example the use of recombinant en-
zymes for reaction phenotyping. Baculovirus- (and other forms of
cDNA-) expressed recombinant human enzymes are a simple system in
which specific metabolic pathways may be identified and large quan-
tities of metabolites may be generated for the purposes of structural
elucidation. They are infrequently used for prediction of overall meta-
bolic clearance due to the need to assess each isozyme individually.
In vitro characterisation of CCT241736 metabolism in human and
four preclinical species (dog, minipig, rat and mouse) was undertaken.
Intrinsic clearance (CLint) determinations were performed in both liver
microsomes and cryopreserved hepatocytes and metabolite identifica-
tion was undertaken across all matrices. Additionally, recombinant
human CYP (rCYP) were utilised to identify the enzymes likely to be
responsible for metabolism of CCT241736 in human.
2. Materials and methods
2.1. Materials
Cryopreserved human hepatocytes (mixed gender, 20 donors, lot
FHQ), Beagle dog hepatocytes (male, 3 donors, Lot FDY; female, 3
donors, Lot JQI) and liver microsomes (DLM) (male, 3 donors, Lot USY;
female, 3 donors, Lot APD), Gottingen minipig hepatocytes (male, 3
donors, Lot YNL; female, 3 donors, Lot DPM) and liver microsomes
(PLM) (male, 3 donors, Lot NVB; female, donors unknown, Lot VPI),
Sprague Dawley rat hepatocytes (female, 21 donors, Lot PCS) and ICR/
CD-1 mouse hepatocytes (female, 54 donors, Lot SQW) were purchased
from BioIVT (Frankfurt Am Main, Germany). Hepatocyte thawing
medium (InVitroGRO HT medium) was also purchased from BioIVT.
ICR/CD-1 mouse liver microsomes (MLM) (female, 800 donors, Lot
1310224), Sprague Dawley rat liver microsomes (RLM) (female, 200
donors, Lot 1110040) and human liver microsomes (HLM) (mixed
gender, 50 donors, Lot 1410013) were purchased from Sekisui
XenoTech, LLC (Kansas City, USA). CYP1A2LR, CYP2B6LR, CYP2C8LR,
CYP2C9HR, CYP2C19LR, CYP2D6LR, CYP2E1R, CYP3A4LR and
CYP3A5BLR EasyCYP bactosomes (each 1 nmol P450/ml co-expressed
with human CYP reductase) and inactive control human rCYP bacto-
somes were purchased from Cypex Limited (Dundee, UK). Williams'
Medium E (WME) was purchased from Scientific Lab Supplies Ltd.
(Nottingham, UK). 100mM potassium phosphate buffer (KPB) adjusted
to pH 7.4 was prepared in house. All other compounds and reagents
were purchased from Sigma-Aldrich Company Ltd. (Dorset, UK). All
solvents were obtained from Greyhound Chromatography and Allied
Chemicals (Birkenhead, UK). Test and control compound stocks were
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prepared as 10mM or 1mM solutions in DMSO. Olomoucine (500 nM
in methanol) was used as an internal standard throughout.
2.2. Storage and thawing of cryopreserved hepatocytes
Cells were stored in the vapour phase of liquid nitrogen and thawed
as per the supplier's instructions (rapid thawing at 37 °C, followed by
centrifugation at 50×g for 5min in thawing medium). Hepatocytes
were re-suspended in a small volume of incubation medium (WME
buffered with HEPES (final concentration 24mM) adjusted to pH 7.4).
Cell density was estimated using a haemocytometer and light micro-
scope and viability determined according to the trypan blue exclusion
method; cells were subsequently diluted to the required concentration
in incubation medium.
2.3. Incubation of hepatocyte suspensions
Suspended hepatocyte incubations for the purposes of metabolite
identification and CLint determination were conducted as described by
Wood et al. (2018) in round-bottomed 350 μl 96-well polypropylene
plates on a PHMP thermoshaker (Grant Instruments (Cambridge) Ltd.
(Shepreth, UK)) at 37 °C and 900 rpm. 60 μl of hepatocytes at twice the
desired final concentration (Table 1) was pre-incubated for 5min under
the above conditions; 60 μl of CCT241736 (final concentration 1 μM) in
incubation medium was added to initiate the reaction. Individual wells
were quenched with 120 μl of methanol containing internal standard
over a time course (Table 1) and an aliquot removed for analysis.
2.4. Incubation of subcellular fractions and recombinant enzymes
All incubations of subcellular fractions and recombinant enzymes
were conducted at 37 °C and 800 rpm using a Hamilton Microlab Star
liquid handling workstation (Hamilton Robotics (Bonaduz,
Switzerland)).
2.4.1. Microsomal incubations
CCT241736 (final concentration 1 μM) was pre-incubated for
10min in PLM, DLM, MLM, RLM or HLM (final concentration 1mg/ml
prepared in 10mM phosphate buffered saline (PBS)). Prior to initiation
of the reaction by the addition of NADPH (final concentration 1mM),
an aliquot was removed from each incubation and quenched in ice cold
methanol containing internal standard (referred to as T0). NADPH was
subsequently added to this solution for matrix matching. The remaining
reaction (with addition of NADPH) was allowed to proceed for 60min.
At 0.5, 5, 15, 30 and 60min aliquots were sampled and quenched as
above. Incubations were conducted in singlicate; control incubations
(substituting PBS for NADPH) were conducted simultaneously.
2.4.2. Reaction phenotyping using recombinant CYP
Recombinant CYP (100 pmol P450/ml) and control bactosome (at
an equivalent protein concentration) were prepared in 100mM KPB.
CCT241736 (final concentration 1 μM) was pre-incubated for 3min
with each of rCYP1A2, rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C19,
rCYP2D6, rCYP2E1, rCYP3A4 and rCYP3A5 and control. The reaction
was initiated by the addition of NADPH (final concentration 1mM) and
allowed to proceed for 20min. At T0 (see Section 2.4.1), 0.5, 5, 10, 15
and 20min, an aliquot was removed from each incubation and quen-
ched in ice cold methanol containing internal standard.
2.5. Protein binding studies
The fraction unbound in microsomes and rCYP (fumic and fuCYP
respectively) of CCT241736 was measured using a Rapid Equilibrium
Dialysis device (Thermo Fisher Scientific, Loughborough. UK). HLM
(1mg/ml) and control rCYP (100 pmol/ml) containing 1 μM
CCT241736 were dialysed against 100mM KPB for 4 h at 37 °C.
Samples were removed, matrix matched and quenched with methanol
containing internal standard; further processing is as described in
Section 2.6.
2.6. Sample preparation and liquid chromatography-mass spectrometry
analysis
Terminated hepatocyte incubations were stored in a −20 °C freezer
for at least 1 h before further processing. All samples were centrifuged
at 3700 rpm at 4 °C using an Eppendorf 5810 R centrifuge (Eppendorf
UK Limited, Stevenage, UK) for 30min to precipitate protein and enable
sampling of supernatant prior to appropriate dilution for liquid chro-
matography-mass spectrometry (LC-MS(/MS)) analysis.
For the purpose of CLint determination, samples were analysed using
an Agilent 1290 Infinity ultra high-performance liquid chromatography
(UHPLC) system coupled to an Agilent 6520 Quadrupole Time-of-flight
mass spectrometer (Agilent Technologies, Stockport, UK). Separation of
analytes was achieved using a Phenomenex Kinetex C18 column
(2.6 μm, 50×2.1mm) (Phenomenex, Macclesfield, UK) at a tempera-
ture of 55 °C and a binary mobile phase gradient at a flow rate of
0.6 ml/min. Initial LC conditions comprised 90% solvent A (0.1%
formic acid in water), 10% solvent B (methanol); this was ramped to
100% B at 3min, held for 1min and then immediately returned to in-
itial conditions and held for the remaining 2min of the method. Sample
analysis was by electrospray atmospheric pressure ionization combined
with full scan acquisition in positive ion mode over a mass range
100–1000 m/z. The capillary voltage was 4 kV, desolvation gas was
350 °C.
For the purpose of metabolite identification, samples were analysed
using a Dionex Ultimate 3000 UHPLC system coupled to a
ThermoScientific Q Exactive Plus orbitrap mass spectrometer (Thermo
Fisher Scientific Inc., Waltham, USA). Separation of analytes was
achieved using an Acquity UPLC HSS T3 column (1.8 μm,
100× 2.1mm) (Waters, Elstree, UK) at a temperature of 50 °C and a
binary mobile phase gradient at a flow rate of 0.4 ml/min. Initial con-
ditions comprised 10% solvent A (0.1% formic acid in water), 90%
solvent B (methanol); this was ramped to 95% A at 12min, immediately
returned to initial conditions and held for the remaining 3min of the
method. The UV absorbance of samples at 230 nm and 260 nm was
monitored using a Dionex Ultimate 3000 diode array detector. Sample
analysis was by electrospray atmospheric pressure ionization combined
with full scan acquisition in positive ion mode over a mass range
80–1200 m/z. The capillary voltage was 3.5 kV; desolvation gas and
capillary temperatures were 450 °C and 275 °C respectively; sheath, aux
and sweep gas flow rates were 55, 15 and 3 respectively. Full MS/dd-
MS2 (full MS scan followed by data dependent MS/MS) and Full MS/
AIF (full MS scan followed by all ion fragmentation) workflows were
used in combination. Parameters for these workflows are given in
Table 1 of the Appendix.
2.7. Metabolite identification
Identification of metabolites and elucidation of their proposed
Table 1
Incubation conditions of CCT241736 in cryopreserved hepatocyte suspensions.
Species Sex Hepatocyte density (final)
(106 cells/ml)
Sampled incubation time points
(min)
Human Mixed 2.5 0, 20, 40, 60, 90, 120
Dog Male 1 0, 10, 20, 40, 60, 90, 120, 180
Female 1 0, 5, 10, 20, 40, 60, 90, 120
Minipig Male 1 0, 10, 20, 40, 60, 90, 120, 180
Female 1 0, 2.5, 5, 10, 20, 30, 40, 60
Rat Female 1 0, 10, 20, 30, 40, 60, 90, 120
Mouse Female 0.25 0, 10, 20, 30, 40, 60, 90, 120
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structures was undertaken with the aid of the software Compound
Discoverer (v2.0.0.303, Thermo Fisher Scientific Inc., Waltham, USA).
RAW data files containing accurate mass data and fragmentation
spectra generated in the acquisition software Chromeleon (v7.2 SR3
(7553), Thermo Fisher Scientific Inc., Waltham, USA) were input into
Compound Discoverer and processed using the targeted workflow de-
scribed in Fig. 1 of the Appendix. The final time point of a parallel
incubation of a different compound was used as a sample blank and any
chromatographic peaks identified with the same m/z and retention time
as in this sample were marked as background compounds and therefore
not considered as potential metabolites. The Compound Discoverer
application combines accurate mass data, isotope pattern matching and
predicted biotransformations based on the parent compound's structure
to generate a series of expected and unexpected compounds or meta-
bolites. These were manually filtered using a typical criteria of peak
area greater than or equal to 5000 counts per sec; compound identified
in samples of at least three time points and peak area ratio of compound
in Tx relative to T0 greater than or equal to 2, where Tx represents any
given time point. Visual inspection of the chromatograms was under-
taken to identify analytes exhibiting a change in intensity consistent
with that of a metabolite. The fragmentation spectra of these analytes
were compared to those of the parent to facilitate structural inter-
pretation of biotransformations.
2.8. Computational chemistry
The protein–ligand co-crystal structure of Aurora-A kinase (Protein
Data Bank (PDB) 2x6e) (Bavetsias et al., 2010) was prepared for
modelling using Protein Preparation Wizard (Maestro v11.2, Schrö-
dinger, LLC: New York, USA, 2017). To predict proposed binding poses
of the ligands, Glide (Grid-based Ligand Docking with Energetics) (v7.5,
Schrödinger, LLC, New York, USA, 2017) was used for the docking
experiments. The receptor grid was defined by a grid box of
30×30×30 Å with a default inner box (10×10×10 Å) (Glide v7.5,
Schrödinger, LLC, New York, USA, 2017) centred on the crystallized
ligand (compound 51 (Bavetsias et al., 2010)) in the Aurora-A binding
site in structure PDB 2x6e. Ligands were prepared using LigPrep (v4.2,
Schrödinger, LLC: New York, USA, 2017), applying the OPLS_2005
force-field with possible tautomeric and ionization states within pH
range 5.0–9.0 generated using Epik ionization settings. Using Glide
Extra Precision (XP) settings, flexible docking of ligands was performed
unconstrained.
2.9. Metabolite isolation and purification
In order to generate sufficient quantity of M1 to be sent for Kd de-
termination, multiple rCYP3A4 incubations (equivalent to those de-
scribed in Section 2.4.2) were conducted in parallel. The supernatant
generated by centrifugation (as described in Section 2.5) of quenched
samples was pooled and evaporated to dryness using a Biotage V-10
Touch evaporator (Biotage, Uppsala, Sweden). Sample was recon-
stituted in 5ml of 1:1 methanol:water and centrifuged at 5000 rpm for
5min; 4×1ml of the supernatant was transferred to 1.5 ml vials for
separation via HPLC. Chromatographic separation was performed using
an Agilent 1260 Series HPLC (Agilent, Santa Clara, USA) and a ZORBAX
Eclipse XDB-C18 column (4.6× 150mm, 5 μm) (Agilent, Santa Clara,
USA) at a temperature of 30 °C. 50 μl injections were run over a 12min
gradient elution at 10–95% B at a flow rate of 1ml/min (organic sol-
vent B: methanol, aqueous solvent A: 0.1% formic acid in water).
UV–vis spectra were acquired at 210 nm, 254 nm and 280 nm on a 1260
Series diode array detector (Agilent Santa Clara, USA). The fractions
were collected using a 1260 Agilent analytical scale fraction collector.
Raw data was processed using Agilent Chemstation software (v C.01.05,
Agilent, Santa Clara, USA). The same fractions collected from multiple
injections were pooled and dried using a Biotage V-10 Touch eva-
porator. Isolated M1 was confirmed by LC-MS as described in Sections
2.5 and 2.6.
2.9.1. NMR
The absolute weight of the purified M1 was determined by quanti-
tative 1H NMR (Nuclear Magnetic Resonance) using the Bruker
ERETIC2 method.
0.5ml of methanol‑d4 was added to the dried M1 fraction collected
in Section 2.8. The concentration of the sample was obtained by
quantitative 1H NMR and the absolute weight of M1 was calculated. M1
was then recovered by evaporating methanol‑d4 using a Smart Eva-
porator (Asynt, Iselham, UK). 3.33mM DMSO stock solution was then
prepared according to the absolute weight of M1. The parent compound
CCT241736 was used in parallel as a control.
NMR data was collected on a Bruker Avance NEO spectrometer
equipped with 600MHz magnet and 5mm TCI Cryoprobe (Bruker,
Massachusetts, USA). The 1H spectrum was referenced to the internal
deuterated solvent. The operating frequency for 1H was 600MHz. All
NMR data were acquired at the temperature of 298 K. Data was ac-
quired and processed using Bruker Topspin (v4.0, Bruker,
Massachusetts, USA). The quantitative 1H NMR spectrum was acquired
using a Bruker standard 1D zg pulse sequence with 4 scans. The sweep
width was 19.8 ppm, and the FID contained 64 k time-domain data
points. Relaxation delay was set to 20 s. The quantitative 1H NMR
spectrum was acquired using an in-house 1D pulse sequence
lc1pngppsf2 with 32 scans. The sweep width was 6.2 ppm, and the FID
contained 16 k time-domain data points. Relaxation delay was set to
20 s.
2.10. Kd determination
Purified solid M1 and parent (CCT241736) were used to prepare
1.665mM DMSO solutions which were sent to DiscoverX Corporation
(Freemont, USA) for Kd determination against Aurora-A, Aurora-B,
FLT3 and FLT3-ITD using the KINOMEscan™ profiling service. Kds were
determined using an 11-point 3-fold compound dilution series (top
concentration 5 μM) with three DMSO control points.
2.11. Data analysis
LC-MS(/MS) data was processed using the relevant associated soft-
ware; either Agilent MassHunter Quantitative Analysis (v. B.06.00,
Agilent Technologies, Stockport, UK) or Chromeleon 7 Chromatography
Data System (v. 7.2 SR3 (7553), Thermo Fisher Scientific Inc.,
Waltham, USA).
In vitro data (parent compound LC-MS response) was fitted to a non-
linear single exponential model using the software GraphPad Prism
(v6.07, GraphPad Software, Inc., La Jolla, USA) to determine the
elimination rate constant (k). CLint in hepatocytes and liver microsomes
was calculated using Eqs. (1) and (2), respectively.
=CL (µl/min/10 cells) V·k
No.of cellsint
6
(1)
=CL (µl/min/mg microsomal protein) V·k
mg proteinint (2)
where CLint is the intrinsic clearance (μl/min/106 cells or μl/min/mg
microsomal protein), V is the incubation volume (μl), No. of cells is the
number of cells in the incubation/106 for hepatocyte assays and mg
protein is the mg microsomal protein in the incubation for microsomal
assays.
CLint in rCYP was calculated using Eq. (3) and scaled to μl/min/mg
microsomal protein using Eq. (4).
=CL (µl/min/pmol P450) V·k
pmol proteinint (3)
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=CL (µl/min/mg microsomal protein) CL (µl/min/pmol P450)·ISEF·
CYP abundance
int int
(4)
where ISEF is the Intersystem Extrapolation Factor and CYP abundance
is amount of each CYP relative to microsomal protein. For rCYP3A4 an
ISEF of 1.09 (Certara, 2017) and a CYP abundance of 137 pmol P450/
mg microsomal protein (Certara, 2017) were used.
The fraction unbound (fu) in HLM/rCYP was calculated using Eq.
(5).
= +f 1/ 1 1 1u PAR receiver
PAR donor (5)
where PAR=Peak Area Ratio of analyte/internal standard.
Unbound CLint (CLint,u) was calculated using Eq. (6).=CL CL /fint,u int u (6)
To enable comparison of metabolites across species and systems,
semi-quantitative analysis of metabolites based on LC-MS response was
performed. % T0 parent response (Eq. (7)) describes the abundance of a
single metabolite at any given time point relative to the initial abun-
dance of the parent. % total metabolite response (Eq. (8)) describes the
abundance of a single metabolite at any given time point as a percen-
tage of the total abundance of parent and all identified metabolites at
that same time point.
=%T parent response LC MS response of metabolite at T
LC MS response of parent at T0
x
0 (7)
where Tx represents any given time point and T0 represents 0min.
=%total metabolite responseLC MS response of metabolite at T
Combined LC MS response of parent and all metabolites at T
x
x
(8)
3. Results
3.1. Comparison of CLint of CCT241736 across in vitro systems and species
The CLint of CCT241736 was determined in hepatocytes and liver
microsomes of human and four preclinical species, namely dog,
minipig, rat and mouse (Table 2). In human, rat, dog and minipig he-
patocytes the CLint of CCT241736 was low, ranging between <1–10 μl/
min/106 cells, but was considerably higher in mouse hepatocytes
(91 μl/min/106 cells). Similarly, the microsomal CLint of CCT241736
was highest in mouse (53 μl/min/mg protein); all other species ex-
hibited low microsomal CLint (<10 μl/min/mg protein (Table 2)).
3.2. Metabolite profiling of CCT241736 in vitro
Metabolite profiling of CCT241736 (Fig. 1) was undertaken on all in
vitro matrices studied; 13 metabolites were identified in addition to the
parent compound (m/z, 456.147; retention time (RT), 7.58min). Al-
though UV–vis spectra were acquired for each sample, neither parent
compound nor metabolites were detectable in any unprocessed matrix
due to their low concentration. UV–vis analysis of the concentrated
rCYP3A4 incubate (described in Section 2.8) revealed peaks at 260 nm
for parent, M1 and M4. It is believed that the other CYP3A4 metabolites
were either not generated in sufficient quantity for UV–vis analysis or
became unstable during processing. The ratio of metabolite to parent
based on UV trace peak area and LC-MS response were equivalent for
M1 and M4 suggesting that mass spectrometry signals are adequate
representation of concentration for these metabolites. In the absence of
UV data for the other 11 metabolites, the assumption was made that LC-
MS response was representative of absolute abundance in these in-
stances also.
Structural elucidation of metabolites was performed using accurate
mass data and fragmentation spectra generated during LC-MS/MS
analysis; supporting information is given in Fig. 2A–D of the Appendix.
All metabolites were determined to be either oxidations and/or deal-
kylations of parent. A summary of the identified metabolites and their
maximal abundance (relative to parent at T0) in each matrix is pre-
sented in Fig. 2.
Thirteen metabolites were identified overall; seven of these (five
dealkylations and two mono-oxidations) were present in human in vitro
systems (Fig. 2). At the final sampled time point, the most abundant
metabolite in human, M1, represented 9.4% and 10.6% (hepatocytes
and HLM respectively) of the parent LC-MS response at T0. M2, the
second most abundant metabolite in human, gave an LC-MS response in
hepatocytes and HLM equivalent to between 2 and 4% of parent LC-MS
response at T0. Two additional metabolites (M3 and M4) were found in
both human hepatocytes and HLM and a further three metabolites (M5,
M6 and M7) in HLM only at abundances <2% of T0 parent (based on
LC-MS response).
Similar to human, M1 was highly abundant in minipig (male and
female); however, M2 was of comparably high abundance in this spe-
cies and therefore increased in minipig relative to human. In addition to
those metabolites synonymous with human (M3, M4, M6 and M7), M12
and M13 were identified in PLM (both sexes) and male minipig hepa-
tocytes respectively. In dog, M3 was the major metabolite (maximally
>10% of T0 parent based on LC-MS/MS response) identified in hepa-
tocytes and microsomes of both sexes, whilst M8, a metabolite found
only in dog, showed increased abundance in hepatocytes relative to
microsomes (Fig. 2). M1, M2 and M4 were also present in DLM (both
sexes); M6 and M7 were identified in female DLM only. In rat, the major
metabolite in hepatocytes (M6) was not identified in RLM and the
second most abundant metabolite in hepatocytes (M4) (maximally
Table 2
CLint of CCT241736 in hepatocytes and liver microsomes of human, dog,
minipig, rat and mouse.
Species Sex Hepatocyte CLint
(μl/min/106 cells)
Microsomal CLint
(μl/min/mg protein)
Human Mixed <1 7.8± 1.0
Dog Male 8.4 7.4± 1.4
Female 3.9 9.5± 2.2
Minipig Male 7.0 5.5± 0.9
Female 3.4 5.1± 1.1
Rat Female 10 2.7± 1.8
Mouse Female 91 53±4.1
Fig. 1. Chemical structure of CCT241736.
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8–10% of T0 parent LC-MS/MS response), represented at most <2% of
parent in RLM. Additional minor metabolites identified in rat include
M1, M2, M3, M7, M11 and M12. In mouse, M2 and M7 were major
metabolites (maximally >10% of T0 parent based on LC-MS/MS re-
sponse) in both hepatocytes and MLM; LC-MS/MS response of M4 and
M1 represented between 2 and 8% of initial parent signal. Additional
minor metabolites (<2% T0 parent response) identified in mouse in-
clude M3, M6, M9, M10, M11 and M12 (Fig. 2). Maximal or close to
maximal abundances of metabolite were observed at the final sampled
time point for all species with the exception of mouse, for which some
metabolites notably reached maximal abundance much earlier and
subsequently decreased.
Graphical representation of the in vitro metabolic profile of
CCT241736 across species over time provides further insight into si-
milarities and differences between metabolic pathways which are not
obvious from maximal abundance data. The metabolic profiles of
CCT241736 and its metabolites (as a percentage of total parent and
metabolite response (Eq. (8)) in HLM and MLM are given in Fig. 3A and
B respectively. In HLM, M1 (the most abundant metabolite) shows a
consistent increase over the 60min incubation period, however in
MLM, M1 shows an initial increase (up to 7% total metabolite response)
followed by a slight decrease, potentially indicative of a primary me-
tabolite which is subsequently further transformed. A similar, but more
exaggerated profile is also observed for M4 (Fig. 3B). M2 is the most
abundant metabolite in MLM, increasing to >25% of total metabolite
response within the first 30min of incubation, but levelling off subse-
quently despite a continued increase in the abundance of other
metabolites (e.g.M7). In HLM, M2 is much less abundant, reaching only
3.5% total metabolite response at 60min incubation, highlighting a
species difference in the predominant pathway of CCT241736 meta-
bolism. In HLM, M6 and M7 are undetectable until 15min incubation,
then exhibit a steady increase in abundance, consistent with the profile
of a secondary metabolite. M7 follows a similar profile in MLM al-
though at greater abundance than in HLM. The abundance of M6 in
MLM is too low to discern a meaningful profile.
3.3. Reaction phenotyping of CCT241736 using rCYP
As all biotransformations identified were consistent with Phase I
metabolism, reaction phenotyping studies were conducted only in
rCYPs. Six of the seven metabolites of CCT241736 (M1-M5 and M7)
identified in HLM and human hepatocytes (Fig. 2) were found in single
rCYP incubations. Although metabolites were identified in incubations
of recombinant CYP3A4, CYP3A5, CYP2C9 and CYP2D6, CLint of
CCT241736 could only be accurately determined in rCYP3A4, as de-
pletion of substrate in other rCYP incubations was negligible. The
scaled CLint,u of CCT241736 in rCYP3A4 was equivalent to 4078 μl/
min/mg microsomal protein (fuCYP= 0.0094). This compares to CLint,u
in HLM of 2714 μl/min/mg microsomal protein (fumic= 0.0018). As
well as being the major contributor to the overall CLint of CCT241736,
CYP3A4 was demonstrated to be responsible for formation of five out of
the seven identified metabolites (M1, M2, M4, M5 and M7). All meta-
bolites identified in rCYP3A4 incubations were also found in incuba-
tions of rCYP3A5. M3 was observed in incubations of both recombinant
H R M
Mixed M F M F F F
Heps • 0-2
Mics • 2-4
Heps • • • • • • 4-8
Mics • • • • • • • • 8-10
Heps • • • • • • >10
Mics • • • • • • •
Heps • • • • • •
Mics • • • • • • •
Heps • • • • • • •
Mics • • • • • • •
Heps
Mics •
Heps • • • •
Mics • • • • •
Heps • •
Mics • • • • • •
Heps • •
Mics • •
Heps
Mics •
Heps
Mics •
Heps • •
Mics
Heps • •
Mics • • • •
Heps •
Mics
M13 - C7H5Cl 332.139 5.91
M11 - CH2 + O 458.126 7.50
M12 - C7H5Cl + O 348.133 6.30
M9 + O 472.141 6.10
M10 + O 472.141 7.75
M7 - C9H7Cl 306.123 3.75
M8 - CH2 + O 458.126 6.90
M5 + O 472.141 6.82
M6 - C8H7Cl 318.123 4.10
M4 - C2H2 430.131 5.85
M1 - C7H5Cl 332.139 4.70
M2 + O 472.141 7.96
Symbol
Maximal % of T0 
Parent Response
M3 - CH2 442.131 7.22
Metabolite
Change relative 
to parent
m/z
RT 
(min)
System
D P
P Parent 456.147 7.58
Fig. 2. Metabolites of CCT241736 and their maximal abundance (at any time point) relative to parent at T0 in hepatocytes and liver microsomes of human, dog,
minipig, rat and mouse. RT, retention time; H, human; D, dog; P, minipig; R, rat; M, mouse.
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CYP2D6 and CYP2C9, however no distinguishable loss of parent was
observed in such incubations, precluding calculation of CLint. M6
(identified in HLM) was not observed across any incubations of a single
rCYP and is therefore proposed as a secondary metabolite formed via
sequential metabolism by multiple CYPs.
3.4. Docking of M1 to Aurora and FLT3
Molecular docking experiments were conducted to predict the
binding of CCT241736 and M1 to Aurora-A and FLT3 kinases. As there
are over 100 Aurora-A structures reported in the PDB (Berman et al.,
2000), the crystal structure of Aurora-A with a structural analogue of
the same series of inhibitor (compound 51 (Bavetsias et al., 2010))
bound (PDB 2x6e) was selected for docking experiments. This kinase
structure adopts an ‘active’ conformation that typically binds ‘type-I’
kinase inhibitors, and the protein conformation is compatible with ADP
binding. Using this structure, both ligands (CCT241736 and M1) were
predicted to adopt a similar binding mode to the bound inhibitor
compound 51 (Fig. 5) (Bavetsias et al., 2010). On the contrary, there
are only a few FLT3 kinase structures reported in the PDB. They all
adopt an ‘inactive’ conformation that typically binds ‘type-II' kinase
inhibitors, and the protein conformation is incompatible with ADP
binding. Although CCT241736 and M1 could be modelled into an ADP-
incompatible binding pocket, it would be illogical to propose such a
binding mode prediction given that these compounds would be ex-
pected to behave like type-I kinase inhibitors and therefore be ADP-
competitive. Hence, a binding pose of these compounds in FLT3 is not
reported.
3.5. Isolation, purification and activity of M1
Due to the abundance of M1 (maximally approximately 10% of
parent) in human hepatocytes and liver microsomes, it was decided to
screen M1 for activity against all targets of the parent compound. For this
to be possible, μg quantities of the metabolite were required. M1 was
successfully isolated and purified using the methods described in
Sections 2.9 and 2.9.1 and was sent to DiscoverX Corporation for selected
Kd determinations. M1 was found to at least retain activity against FLT3,
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Fig. 3. Profile of CCT241736 metabolites following 1 μM incubation in human (A) and mouse (B) liver microsomes of protein concentration 1mg/ml. Values are
percentage of total mass spectrometric response.
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although potency against FLT3-ITD, Aurora-A and Aurora-B was reduced
compared to parent compound CCT241736 (Table 3).
4. Discussion
In vitro assessment of the metabolism of CCT241736 was undertaken
in human and four pre-clinical species (dog, minipig, rat and mouse)
with the aim to establish which species would be most suitable for
toxicology studies.
CCT241736 exhibited low CLint in hepatocytes and liver microsomes
of human, dog, minipig and rat, not exceeding 10 μl/min/106 cells and
10 μl/min/mg protein respectively. The CLint of this compound in
mouse hepatocytes and liver microsomes was considerably higher at
91 μl/min/106 cells and 53 μl/min/mg protein respectively. However,
as it is not uncommon for the CLint of a compound to be greater in
smaller mammalian species than in human (Naritomi et al., 2001;
Nishimuta et al., 2013; Sakai et al., 2014), the overall metabolic profile,
together with pharmacokinetics and pharmacodynamics, bears greater
influence in selection of a toxicology species.
Metabolite identification was performed for all studied matrices.
Although UV spectra were acquired, the low assay substrate con-
centration and turnover precluded metabolite quantification by this
method. Instead, semi-quantitative analysis of metabolites based on LC-
MS response relative to that of the parent was performed, with the
obvious caveat to data interpretation being the assumption that all
metabolites share the same ionization efficiency as the parent com-
pound. Although this may be considered unlikely, the ratio of M1 to
parent in the concentrated rCYP3A4 incubate was the same whether
based on LC-MS response or UV absorbance at 260 nm. This lends
support to the reported relative abundances of each metabolite and the
conclusion that M1 is the most abundant metabolite in human in vitro
systems.
Of the two larger mammalian species, minipig showed greatest si-
milarity to human with regard to both overall metabolic profile and
maximal abundance of specific metabolites relative to parent (Fig. 2).
Dog was considered to be a less appropriate toxicology model due to the
increased abundance of M3 (relative to parent) and the presence of M8,
a metabolite uniquely identified in dog, also at relatively high levels (up
to 8% of initial parent response).
In rodents, 6 out of 7 metabolites found in human were also ob-
served in both rat and mouse, with additional low abundance meta-
bolites identified in both species. Although there appears to be con-
siderable dissimilarities in the abundance of specific metabolites of
CCT241736 in rodents and human (Fig. 2), at least for mouse, these
may reflect the higher CLint in this species, rather than differences in the
predominance of certain metabolic routes. For example, M2 is a pri-
mary metabolite which is not believed to undergo further bio-
transformation; the increased abundance of M2 in mouse relative to
human is therefore consistent with increased overall metabolism of the
parent compound. The same principle could be argued for M6 in rat
hepatocytes; its apparent absence in RLM and human hepatocytes re-
presentative of the reduced turnover of parent in these systems. Overall
both mouse and rat in vitro systems provide good representation of
human metabolites observed in vitro.
M5, a mono-oxidation, was the only human metabolite not to be
identified in any of the investigated pre-clinical species. However, as it
is only present in HLM at very low abundance, it is not considered a
significant cause for concern.
Notably, all metabolites identified in human hepatocytes were also
present in HLM (supplemented with NADPH only), indicating that all
detectable metabolism of CCT241736 was mediated by CYPs or mi-
crosomal enzymes which do not require exogenous cofactors. Reaction
phenotyping of CCT241736 was therefore undertaken using re-
combinant cytochrome P450 bactosomes, of which those containing the
nine most common drug metabolising enzymes were selected.
Incubation of CCT241736 with individual rCYPs revealed CYP3A4 to be
the predominant enzyme in the metabolism of this compound, re-
sponsible for formation of five out of seven observed metabolites (M1,
M2, M4, M5 and M7) and postulated to be involved in the formation of
a sixth (M6). Indeed, the scaled CLint of CCT241736 in rCYP3A4 ex-
ceeded that observed in HLM. Whilst discrepancies in the total clear-
ance of a compound between such systems are not unexpected due to
inaccuracy in the ISEF value and/or protein binding, this result con-
firms CYP3A4 as the major contributor to oxidative metabolism of
CCT241736. Consequently, co-administration of CCT241736 and
CYP3A4 inhibitors (such as the azole antifungals often used prophy-
lactically in cancer treatment (Cronin and Chandrasekar, 2010)) is
therefore likely to be contraindicated. CYP2C9 and CYP2D6 were the
only other CYPs found to metabolise CCT241736; M3 was identified in
incubations with each of these enzymes. The absence of M6 from any
individual rCYP incubation implies the involvement of multiple en-
zymes in its production and, owing to the structural similarities be-
tween these metabolites, M6 is postulated to be formed by secondary
metabolism of M1 and/or M3. Yet, as this has not been experimentally
determined, the conversion of M1 to M6 and M3 to M6 by CYP2C9/2D6
and CYP3A4 respectively is asterisked and accompanied by dashed
arrows in Fig. 4. M7 is also believed to be a secondary metabolite, al-
though only CYP3A4/5 are implicated in its production. This notion is
based on the profile of M7 in mouse (undetectable until 15 min, but
increasing subsequently) and its structural similarity to both M1 and
M4. Indeed, the profiles of M1 and M4 in MLM suggest that both un-
dergo further metabolism (Fig. 3B). The presence of M7 in HLM in-
dicates that CCT241736 follows the same or a similar metabolic
pathway in human as in mouse; its apparent absence in human hepa-
tocytes is likely a consequence of its very low clearance coupled with
analytical limitations of sensitivity. M7 is therefore proposed as a sec-
ondary metabolite of M1 and/or M4 in human, but as for M6, these
pathways are represented by dashed arrows to highlight this un-
certainty. Since it was concluded that all seven metabolites previously
identified in human hepatocytes and HLM were plausibly formed by
one or more rCYPs, it was deemed that no further investigation of re-
action phenotyping was required.
As the most abundant metabolite in human in vitro systems (maxi-
mally approximately 10% of T0 parent based on LC-MS response in both
hepatocytes and liver microsomes), it was prudent to test the activity of
M1 against the targets of the parent compound (Aurora kinases A and B,
FLT3 and FLT3-ITD). M1 was prepared by large scale incubation of
CCT241736 with rCYP3A4 followed by separation by HPLC and sample
concentration. Importantly, M1 was found to retain activity against
FLT3 (Kd=7.9 nM, compared to 6.2/26 nM for parent), but some drop-
off was seen for Aurora-A, Aurora-B and FLT3-ITD (Table 3). The re-
duced potency for Aurora-A is consistent with the predicted binding
pose of M1 obtained from the molecular docking study (Fig. 5). Whilst
this metabolite is not expected to exceed 10% of circulating levels of
parent in vivo and therefore does not warrant additional toxicological
testing, such information may be a useful input into pharmacokinetic-
pharmacodynamic (PKPD) modelling of the parent compound.
In conclusion, in vitro assessment of the metabolism of CCT241736
in human and four pre-clinical species was undertaken. Based on the
metabolic information, selection of minipig as the larger mammalian
Table 3
Activity of CCT241736 and M1 against FLT3, FLT3-ITD, Aurora-A and Aurora-
B.
Compound Kd (nM)
FLT3 FLT3-ITD Aurora-A Aurora-B
CCT241736a 6.2 38 7.5 48
CCT241736 26 34 9.8 64
M1 7.9 82 33 130
a Data taken from Bavetsias et al. (2012).
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species for toxicology studies is justified. In addition, the minipig also
shows greater similarities to human than the dog in both intestinal and
heart physiology and electrophysiology (Singh et al., 2016), therefore
increasing the likelihood that any adverse effects relating to these
systems in human will be identified prior to administration. The me-
tabolic profile of CCT241736 in mouse and rat was sufficiently similar
to human for either to be an appropriate toxicology species, albeit CLint
was higher in mouse. In light of the increased data available for this
CYP3A4
M1
M3 M6
Parent 
(CCT241736)
M7M4
M2
M5
CYP2C9/2D6
CYP3A4/5
CYP3A4
CYP3A4/5
CYP3A4
*CYP2C9/2D6
*CYP3A4
CYP3A4
Fig. 4. Proposed in vitro metabolic biotransformation pathway for CCT241736 in human. Bold arrows represent predominance of these metabolic pathways. Dotted
arrows and asterisked enzymes represent postulated secondary metabolic pathways based on known metabolite structures and primary biotransformations.
Fig. 5. Predicted binding mode of CCT241736 (dark grey) (A) and M1 (dark grey) (B) overlaid with the bound inhibitor compound 51 (cyan) in Aurora-A crystal
structure (PBD 2x6e).
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compound from earlier PKPD and therapy studies in human tumour
xenograft mouse models, mouse was selected as the rodent toxicology
species. All human metabolites of CCT241736 are believed to be pro-
duced by CYPs, CYP3A4 being the major enzyme responsible for me-
tabolism of this compound. The most abundant human metabolite in
vitro (M1) was demonstrated to retain activity against FLT3, but ex-
hibited some loss of activity against Aurora-A, as well as Aurora-B and
FLT3-ITD. This study provides valuable information to support the
further progression of CCT241736 as a candidate for the treatment of
AML.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejps.2019.04.004.
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